Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of Aversion Technology related product candidates. The company's Aversion Technology acts as a platform for developing multiple opioid analgesic products candidates containing codeine, propoxyphene, morphine, hydrocodone, oxycodone, tramadol, and various other opioid analgesics. Its opioid analgesic products are used to relieve pain, as well as to discourage common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize opioid analgesic products, including Acurox tablets, an orally administered immediate release tablet containing oxycodone HCl; Acuracet tablets containing oxycodone HCl/niacin/APAP; and Vycavert tablets containing hydrocodone bitartrate/niacin/APAP utilizing the Aversion Technology in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

Key Statistics

Closing Price	2.67
Volume	41864
Volume Avg	88638
52 Week High	9.13
52 Week Low	2.22
PE	N/A
PE (group average)	78
EPS Year	-0.40
EPS change Q/Q	-0%
EPS change Q/Q Yr ago	-28.57%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-1000%
REV change Q/Q	0%
REV change Q/Q Yr ago	-89.74%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%